Latest Information Update: 23 Jan 2003
At a glance
- Originator AstraZeneca
- Mechanism of Action Pyruvate kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 23 Jan 2003 Discontinued for Diabetes mellitus in Europe (unspecified route)
- 18 Jan 2002 Investigation in Diabetes mellitus in Europe (Unknown route)